ABSTRACT
The Runt domain proteins are eukaryotic transcription factors that regulate major developmental pathways. All members of this family contain a highly-conserved sequence-specific DNA binding domain: the Runt domain (RD). Structural and biochemical studies have shown that the Runt domain undergoes a conformational transition upon binding to DNA and that this process is regulated by an unrelated partner protein CBFbeta that enhances the DNA binding affinity of RD. Most of the reported studies on the Runt domain transcription factors were performed on proteins from mammals and Drosophila whereas very little has been known about the C. elegans RD protein, RUN, which provides the simplest model system for understanding the function of this class of transcription factors. We performed computational studies on RD domains from various species including C. elegans, Drosophila, and human, using the atom-atom contact surface area scoring method. The scoring analysis indicates that the DNA binding regulation of the C. elegans RD protein (CeRD) occurs via its interaction with a CBFbeta-like partner, as found for the human proteins, whereas a different mode of regulation may occur in the Drosophila system. Sequence, secondary structure and fold analyses of a putative CBFbeta protein identified in the C. elegans genome, CeCBFbeta, sharing a 22% identity with the human protein, predict a similar structure of this protein to that of the human CBFbeta protein. We produced the C. elegans proteins CeRD and CeCBFbeta in bacteria and confirmed their physical interaction as well as cross interactions with the corresponding human proteins. We also confirmed the structural similarity of CBFbeta and CeCBFbeta by circular dichroism analysis. The combined results suggest that a similar mechanism of regulation operates for the human and the C. elegans RD proteins despite the low sequence identity between their CBFbeta proteins and the evolutionary distance between the two systems.
Subject(s)
Caenorhabditis elegans Proteins/genetics , Caenorhabditis elegans/genetics , Core Binding Factor alpha Subunits/genetics , Amino Acid Sequence , Animals , Binding Sites , Caenorhabditis elegans Proteins/chemistry , Cloning, Molecular , Core Binding Factor alpha Subunits/chemistry , DNA, Complementary/genetics , Humans , Molecular Sequence Data , Mutagenesis , Protein Biosynthesis , Protein Conformation , Recombinant Proteins/chemistry , Sequence Alignment , Sequence Homology, Amino AcidABSTRACT
The human immunodeficiency virus type 1 (HIV-1) auxiliary gene vif is essential for virus propagation in peripheral blood lymphocytes, macrophages, and in some T-cell lines. Previously, it was demonstrated that Vif inhibits the autoprocessing of truncated HIV-1 Gag-Pol polyproteins expressed in bacterial cells, and that purified recombinant Vif and Vif-derived peptides inhibit and bind HIV-1 protease (PR). Here we show that Vif interacts with the N-terminal region of HIV-1 PR, and demonstrate that peptide derived from the N-terminal region of PR abrogates Vif function in non-permissive cells. Specifically, we show that (i) Vif protein binds HIV-1 PR, but not covalently linked tethered PR-PR; (ii) the four amino acids residing at the N terminus of HIV-1 PR are essential for Vif/PR interaction; (iii) synthetic peptide derived from the N terminus of HIV-1 PR inhibits Vif/PR binding; and (iv) this peptide inhibits the propagation of HIV-1 in restrictive cells. Based on these data, we suggest that Vif interacts with the dimerization sites of the viral protease, and that peptide residing at the N terminus of PR abrogates Vif function(s).
Subject(s)
Gene Products, vif/antagonists & inhibitors , Gene Products, vif/physiology , HIV Protease/pharmacology , Base Sequence , DNA Primers , HIV Protease/chemistry , HIV Protease/isolation & purification , HIV-1/genetics , HIV-1/isolation & purification , HeLa Cells , Humans , Lymphocytes/virology , Peptide Fragments/pharmacology , Recombinant Fusion Proteins/metabolism , Transfection , beta-Galactosidase/genetics , beta-Galactosidase/metabolism , vif Gene Products, Human Immunodeficiency VirusABSTRACT
A drug composition consisting of nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs) is commonly used in AIDS therapy. A major difficulty encountered with the therapeutic composite involves the emergence of drug-resistant viruses, especially to the PIs, regarded as the most effective drugs in the composition. We present a novel bioelectronic means to detect the appearance of mutated HIV-1 exhibiting drug resistance to the PI saquinavir. The method is based on the translation of viral RNA, the association of cleaved or uncleaved Gag polyproteins at an electrode surface functionalized with the respective antibodies, and the bioelectronic detection of the Gag polyproteins associated with the surface. The bioelectronic process includes the association of anti-MA or anti-CA antibodies, the secondary binding of an antibody-horseradish peroxidase (HRP) conjugate, and the biocatalyzed precipitation of an insoluble product on the electronic transducers. Faradaic impedance measurements and quartz crystal microbalance analyses are employed to follow the autoprocessing of the Gag polyproteins. The method was applied to determine drug resistance in infected cultured cells and also in blood samples of consenting AIDS patients. The method described here is also applicable to the determination of drug effectiveness in AIDS patients and to screening of the efficiency of newly developed drugs.
Subject(s)
Anti-HIV Agents/therapeutic use , Biosensing Techniques/methods , Drug Resistance, Viral/genetics , Enzymes, Immobilized/chemistry , HIV Infections/drug therapy , HIV-1 , RNA, Viral/analysis , Antibodies, Monoclonal/chemistry , Antibodies, Monoclonal/metabolism , Biosensing Techniques/instrumentation , Cells, Cultured , Electrochemistry/methods , Electrodes , Gene Products, gag/chemistry , Gene Products, gag/metabolism , Genotype , HIV Infections/virology , HIV Protease Inhibitors/adverse effects , HIV-1/drug effects , HIV-1/genetics , HIV-1/metabolism , Humans , Protein Biosynthesis , Saquinavir/adverse effectsABSTRACT
The vif gene, one of the six auxiliary genes of human immunodeficiency virus (HIV), is essential for virus propagation in peripheral blood lymphocytes and macrophages and in certain T-cell lines. Previously, it was demonstrated that Vif inhibits the autoprocessing of truncated HIV type 1 (HIV-1) Gag-Pol polyproteins expressed in bacterial cells, as well as the protease-mediated cleavage of synthetic peptides in vitro. Peptides derived from the aa 78-98 region in the Vif molecule specifically inhibit and bind the HIV-1 protease in vitro and arrest the production of infectious viruses in HIV-1-infected cells. This study demonstrates that (i) purified recombinant Vif protein and HIV-1 but not avian sarcoma leukaemia virus protease specifically bind each other and (ii) the interaction between these two proteins takes place at the N terminus of the protease (aa 1-9) and the central part of Vif (aa 78-98). The data presented in this report suggest a model in which Vif interacts with the dimerization sites of the viral protease.
Subject(s)
Gene Products, vif/metabolism , HIV Protease/metabolism , HIV-1/metabolism , Binding Sites , Dimerization , Dose-Response Relationship, Drug , Gene Products, vif/biosynthesis , Gene Products, vif/genetics , HIV Protease/chemistry , HIV Protease/genetics , HIV Protease Inhibitors/chemical synthesis , HIV Protease Inhibitors/pharmacology , Peptide Fragments/chemical synthesis , Peptide Fragments/pharmacology , Protein Binding , Recombinant Proteins/metabolism , Virus Replication , vif Gene Products, Human Immunodeficiency VirusABSTRACT
Vif, one of the six accessory genes expressed by HIV-1, is essential for the productive infection of natural target cells. Previously we suggested that Vif acts as a regulator of the viral protease (PR): It prevents the autoprocessing of Gag and Gag-Pol precursors until virus assembly, and it may control the PR activity in the preintegration complex at the early stage of infection. It was demonstrated before that Vif, and specifically the 98 amino acid stretch residing at the N'-terminal part of Vif (N'-Vif), inhibits both the autoprocessing of truncated Gag-Pol polyproteins in bacterial cells and the hydrolysis of synthetic peptides by PR in cell-free systems. Linear synthetic peptides derived from N'-Vif specifically inhibit and bind HIV-1 PR in vitro, and arrest virus production in tissue culture. Peptide mapping of N'-Vif revealed that Vif88-98 is the most potent PR inhibitor. Here we report that this peptide inhibits both HIV-1 and HIV-2, but not ASLV proteases in vitro. Vif88-98 retains its inhibitory effect against drug-resistant HIV-1 PR variants, isolated from patients undergoing long-term treatment with anti-PR drugs. Variants of HIV protease bearing the mutation G48V are resistant to inhibition by this Vif-derived peptide, as shown by in vitro assays. In agreement with the in vitro experiments, Vif88-98 has no effect on the production of infectious particles in cells infected with a G48V mutated virus.
Subject(s)
Aspartic Acid Endopeptidases/drug effects , Drug Resistance, Viral , Gene Products, vif , HIV Protease Inhibitors/pharmacology , HIV Protease/drug effects , Membrane Glycoproteins , Peptide Fragments/pharmacology , Amino Acid Substitution , Aspartic Acid Endopeptidases/genetics , Aspartic Acid Endopeptidases/metabolism , Binding, Competitive/drug effects , Cell Line , Dose-Response Relationship, Drug , Drug Resistance, Viral/genetics , Enzyme Activation/drug effects , Gene Products, vif/chemistry , HIV/drug effects , HIV/genetics , HIV/growth & development , HIV Infections/enzymology , HIV Protease/genetics , HIV Protease/metabolism , HeLa Cells , Humans , Mutation , Substrate Specificity , Viral Envelope Proteins/genetics , Viral Envelope Proteins/metabolism , Virus Replication/drug effects , vif Gene Products, Human Immunodeficiency VirusABSTRACT
Human immunodeficiency virus type 1 Gag and Gag-Pol precursors are translated from an mRNA which is indistinguishable from the full-length genomic RNA. The ratio of Gag to Gag-Pol polyproteins is approximately 20:1 and is controlled by a frameshift of the reading frame, which takes place downstream of the p7 nucleocapsid (NC) in the N terminus of the p1 peptide. The viral precursors Gag and Gag-Pol are cleaved by the virus-encoded protease (PR) into the structural proteins, and into p6(Pol), PR, reverse transcriptase and integrase. Due to the frameshift event, the cleavage site at the C terminus of NC coded in the Gag frame (ERQAN-FLGKI) changes either to ERQANFLRED or ERQANFFRED. The results presented in this report demonstrate that the NC released from the Gag-Pol precursor is 8 amino acid residues longer than the NC cleaved from the Gag polyprotein. Our results also show that truncated Gag-Pol precursors bearing cleavage site mutation at the NC/p6(Pol), and/or p6(Pol)/PR junctions, undergo autoprocessing in bacterial and eukaryotic cells, indicating that PR is active when part of the precursor.
